Effect of cilostazol on Schizophrenia
Phase 3
Recruiting
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20180307038989N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Diagnosis of schizophrenia based on DSM-5 criteria
aged 18-64 years
completed consent form by the patient or his family
at least the eighth grade education
Exclusion Criteria
Simultaneous psychiatric disorders
liver disorders
medical illness
Use of opioid substances other than cigarettes
A hypersensitivity reaction or any untoward side effects caused by the drug
Use of other interfering drugs
Serious cognitive impairment
blood or Platelet problem Contradictory with taking medication
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Score in PANSS questionnaire. Timepoint: Before starting the study and at times, 0, 2, 4 and 8 weeks after starting treatment. Method of measurement: Schizophrenia symptoms assessment questionnaire PANSS.;Memory score in digit span. Timepoint: Before starting the study and at times, 0, 2, 4 and 8 weeks after starting treatment. Method of measurement: Digit span questionnaire.;Cognition scoring based on Wisconsin card sorting test. Timepoint: Before starting the study and at times, 0, 2, 4 and 8 weeks after starting treatment. Method of measurement: Wisconsin card sorting test.
- Secondary Outcome Measures
Name Time Method